Use of human prostate-specific antigen in monitoring prostate cancer
- PMID: 7284995
Use of human prostate-specific antigen in monitoring prostate cancer
Abstract
The newly reported human prostate-specific antigen (PA) is a specific histiotypic product of human prostate. With the use of a sensitive enzyme immunoassay, the circulating PA in prostatic cancer patients has been evaluated clinically. In 96 patients with advanced stage of disease (D2) and receiving chemotherapies, the pretreatment serum PA levels were found to be of prognostic value with regard to the patient survival. Ten patients with metastatic prostate cancer were monitored for more than 32 weeks by 183 serial PA values and were found generally to respond to the treatment. Additionally, in another group of 32 patients who underwent curative therapies for localized prostate cancer, 161 serum samples were evaluated during periods of 12 to 114 weeks (average 56 weeks). Of these patients, five developed metastases during follow-up, and all were shown to exhibit increasingly elevated PA values, either corresponding to or preceding the clinical diagnosis of disease recurrence. These results suggest that PA is a new marker with potential value to merit further clinical study.
Similar articles
-
Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer.Cancer Res. 1985 Feb;45(2):886-91. Cancer Res. 1985. PMID: 2578313
-
Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.Cancer Res. 1980 Dec;40(12):4658-62. Cancer Res. 1980. PMID: 6159971
-
[Clinical evaluation of prostate antigen (PA) in prostate cancer].Gan No Rinsho. 1985 May;31(6 Suppl):606-10. Gan No Rinsho. 1985. PMID: 2411962 Japanese.
-
Prognostic value of serum markers for prostate cancer.Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. doi: 10.1080/03008880510030941. Scand J Urol Nephrol Suppl. 2005. PMID: 16019759 Review.
-
Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer.Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S31-7. Am J Clin Pathol. 1994. PMID: 7524305 Review.
Cited by
-
A data-driven approach to improve wellness and reduce recurrence in cancer survivors.Front Oncol. 2024 Apr 11;14:1397008. doi: 10.3389/fonc.2024.1397008. eCollection 2024. Front Oncol. 2024. PMID: 38665952 Free PMC article.
-
Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium.J Pers Med. 2024 Jan 11;14(1):84. doi: 10.3390/jpm14010084. J Pers Med. 2024. PMID: 38248785 Free PMC article. Review.
-
Clinical Biofluid Assays for Prostate Cancer.Cancers (Basel). 2023 Dec 28;16(1):165. doi: 10.3390/cancers16010165. Cancers (Basel). 2023. PMID: 38201592 Free PMC article. Review.
-
A comparative mRNA- and miRNA transcriptomics reveals novel molecular signatures associated with metastatic prostate cancers.Front Genet. 2022 Nov 16;13:1066118. doi: 10.3389/fgene.2022.1066118. eCollection 2022. Front Genet. 2022. PMID: 36468011 Free PMC article.
-
Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.Nat Rev Urol. 2022 Sep;19(9):562-572. doi: 10.1038/s41585-022-00638-6. Epub 2022 Aug 16. Nat Rev Urol. 2022. PMID: 35974245 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical